Clinuvel Pharmaceuticals

Stories

Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path

Markets the only approved EPP therapy

People with erythropoietic protoporphyria feel stabbing pain in strong light, and no oral drug is approved to help them. Disc Medicine's bitopertin passed a 183-patient Phase 3 trial called APOLLO, the company said on Oct. 19, 2026, reopening a path to the FDA after a rejection in February.

Updated Oct 25